middle.news
How Is Invex Therapeutics Advancing Alzheimer’s Drug Amid Rising Losses?
1:52pm on Thursday 12th of February, 2026 AEDT
•
Healthcare
Read Story
How Is Invex Therapeutics Advancing Alzheimer’s Drug Amid Rising Losses?
1:52pm on Thursday 12th of February, 2026 AEDT
Key Points
Net loss doubles to $715,582 for half-year ended 31 December 2025
Ongoing R&D collaboration with Tessara Therapeutics on Exenatide for Alzheimer’s Disease
Renewal of orphan drug designation for Exenatide in Europe for traumatic brain injury
Significant board changes with two directors resigning and two new appointments
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IXC
OPEN ARTICLE